Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.
Mesinkovska N, King B, Zhang X, Guttman-Yassky E, Magnolo N, Sinclair R, Mizuashi M, Shapiro J, Peeva E, Banerjee A, Takiya L, Cox LA, Wajsbrot D, Kerkmann U, Law E, Wolk R, Schaefer G. Mesinkovska N, et al. J Dermatol. 2024 Nov;51(11):1414-1424. doi: 10.1111/1346-8138.17442. Epub 2024 Sep 27. J Dermatol. 2024. PMID: 39328096 Clinical Trial.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Baricitinib for the Treatment of Alopecia Areata.
Freitas E, Guttman-Yassky E, Torres T. Freitas E, et al. Drugs. 2023 Jun;83(9):761-770. doi: 10.1007/s40265-023-01873-w. Epub 2023 May 17. Drugs. 2023. PMID: 37195491 Free PMC article. Review.
International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting.
Zhang AJ, Ball G, Zundell MP, Agüero R, Yee D, Shields A, Asare C, Navrazhina K, Liu W, Foolad N, Kwock J, Tejwani P, Hamade H, Jaleel T, Butler D, Silverberg N, Nattkemper L, Siegel DM, Tan J, Kim BS, Larocca C, Shinohara MM, Ehlert A, Latella J, Guttman-Yassky E, Krueger JG, Strand V, Armstrong AW, Merola JF, Perez-Chada L, Gottlieb AB. Zhang AJ, et al. Among authors: guttman yassky e. J Drugs Dermatol. 2024 Dec 1;23(12):1114-1120. doi: 10.36849/jdd.8363. J Drugs Dermatol. 2024. PMID: 39630678
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
Guttman-Yassky E, Bar J, Rothenberg-Lausell C, Eichenfield L, Grada A, Abuabara K, Chapman M, Calimlim B, Wegzyn C, Gamelli A, Krueger W, Munoz B, Knapp K, Faller R, Crawford J, Silverberg J. Guttman-Yassky E, et al. J Drugs Dermatol. 2023 Apr 1;22(4):344-354. doi: 10.36849/JDD.7473. J Drugs Dermatol. 2023. PMID: 37026893
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Simpson EL, Eichenfield LF, Papp KA, Forman SB, Hebert AA, Gonzalez ME, Gooderham MJ, Hong HC, Prajapati VH, Guttman-Yassky E, Silverberg JI, Seal MS, Krupa D, Almaraz E, Hanna D, Burnett P, Snyder S, Chu DH, Higham RC, Berk DR. Simpson EL, et al. Among authors: guttman yassky e. Dermatitis. 2025 Jan 10. doi: 10.1089/derm.2024.0418. Online ahead of print. Dermatitis. 2025. PMID: 39792455
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials.
Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, Bieber T, Hong HC, Elmaraghy H, Atwater AR, Pierce E, Xu C, Agell H, Gil EG, Simpson E. Guttman-Yassky E, et al. J Am Acad Dermatol. 2024 Dec 27:S0190-9622(24)03414-5. doi: 10.1016/j.jaad.2024.12.026. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39733939
Response to ritlecitinib with or without narrow-band UVB add-on therapy in patients with active nonsegmental vitiligo: results from a phase 2b extension study.
Yamaguchi Y, Peeva E, Adiri R, Ghosh P, Napatalung L, Hamzavi I, Pandya AG, Shore RN, Ezzedine K, Guttman-Yassky E. Yamaguchi Y, et al. Among authors: guttman yassky e. J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03381-4. doi: 10.1016/j.jaad.2024.11.064. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39709084 Free article.
Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database analysis.
Garate D, Thang CJ, Chang CT, Owji S, Murphy TL, Golovko G, Da Rosa JC, Guttman-Yassky E, Wilkerson MG, Gulati N. Garate D, et al. Among authors: guttman yassky e. J Allergy Clin Immunol Pract. 2024 Nov 28:S2213-2198(24)01180-2. doi: 10.1016/j.jaip.2024.11.015. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 39613098 No abstract available.
423 results